2023
Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes.
Mashayekhi M, Nian H, Mayfield D, Devin J, Gamboa J, Yu C, Silver H, Niswender K, Luther J, Brown N. Weight Loss-Independent Effect of Liraglutide on Insulin Sensitivity in Individuals With Obesity and Prediabetes. Diabetes 2023, 73: 38-50. PMID: 37874653, PMCID: PMC10784656, DOI: 10.2337/db23-0356.Peer-Reviewed Original ResearchConceptsEndogenous GLP-1Glucagon-like peptide-1 receptor agonistsPeptide-1 receptor agonistsImproved insulin sensitivityInsulin sensitivityGLP-1GLP-1RGlucagon levelsGlucose levelsMatsuda indexWeight lossHypocaloric dietPostprandial glucoseInhibitor sitagliptinReceptor agonistMetabolic effectsDiet-induced weight lossDipeptidyl peptidase-4 inhibitor sitagliptinGLP-1R agonist liraglutideWeight loss-independent effectsDPP-4 inhibitor sitagliptinDipeptidyl peptidase-4 inhibitionPeptidase-4 inhibitionMixed meal testGLP-1R antagonist
2019
Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome
Devin JK, Nian H, Celedonio JE, Wright P, Brown NJ. Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome. The Journal Of Clinical Endocrinology & Metabolism 2019, 105: dgz028. PMID: 31529097, PMCID: PMC7947776, DOI: 10.1210/clinem/dgz028.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultBiomarkersBlood GlucoseCross-Over StudiesDipeptidyl Peptidase 4Dipeptidyl-Peptidase IV InhibitorsDouble-Blind MethodFemaleFollow-Up StudiesGlucose Tolerance TestHuman Growth HormoneHumansIntra-Abdominal FatMiddle AgedPolycystic Ovary SyndromePrognosisSitagliptin PhosphateYoung AdultConceptsOral glucose tolerance testPolycystic ovarian syndromeVisceral adiposityVascular functionGrowth hormoneOvarian syndromeGH secretionGlucagon-like peptide-1Increased visceral adiposityMaximal glucose responseOvernight GH secretionOvernight growth hormoneEarly insulin secretionGlucose tolerance testVenous samplingCrossover studyVisceral fatCrossover treatmentTolerance testBlood glucoseDPP4 inhibitionInsulin secretionPeak glucoseGlucose levelsPeptide-1
2008
Inhaled Insulin Is Associated with Prolonged Enhancement of Glucose Disposal in Muscle and Liver in the Canine
Edgerton DS, Cherrington AD, Neal DW, Scott M, Lautz M, Brown N, Petro J, Hobbs CH, Leach C, Del Parigi A, Strack TR. Inhaled Insulin Is Associated with Prolonged Enhancement of Glucose Disposal in Muscle and Liver in the Canine. Journal Of Pharmacology And Experimental Therapeutics 2008, 328: 970-975. PMID: 19098161, PMCID: PMC3202424, DOI: 10.1124/jpet.108.146985.Peer-Reviewed Original ResearchConceptsInhalation of insulinPlasma glucose levelsGlucose levelsDiabetic patientsGlucose disposalNet hepatic glucose uptakeGlucose uptakeArterial plasma glucose levelsHepatic sinusoidal insulinBasal plasma levelsNonhepatic glucose uptakeGlucose infusion rateHepatic glucose uptakeInhalation groupInsulin inhalationSubcutaneous insulinPeripheral veinPlasma levelsPortal veinPlasma insulin kineticsInsulin secretionInfusion rateInsulin actionGlucose utilizationInhalation